Archived NCCN Tumor Boards: New Approaches to Treatment of Bladder Cancer
For most patients with muscle-invasive bladder cancer, the preferred treatment approach is either neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy or bladder preservation with concurrent chemoradiotherapy; however, bladder preservation approaches are currently underutilized, even in patient populations who would benefit most from these approaches. In addition, results from recent clinical trials and new FDA approvals have led to a potential paradigm shift in how metastatic or locally advanced urothelial bladder cancer is treated. This activity will help clinicians identify the best treatment options for their patients with bladder cancer.
Target Audience
This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants/associates, pharmacists, and other health care professionals who manage patients with cancer.
Learning Objectives
Following this activity, participants should be able to:
- Discuss the role of the multidisciplinary care team for treatment of muscle-invasive bladder cancer and how locoregional therapy may be used for bladder preservation approaches.
- Describe new and emerging systemic therapy options for patients with metastatic urothelial bladder cancer and how patient and disease characteristics can guide therapy choice.
- Review the results of recent clinical trials for treatment of bladder cancer and their potential impact on treatment.
Thomas W. Flaig, MD
University of Colorado Cancer Center
Janet Kukreja, MD
University of Colorado Cancer Center
Tyler Robin, MD, PhD
University of Colorado Cancer Center
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Faculty Disclosures
The faculty listed below have no financial relationships with ineligible companies to disclose.
Tyler Robin, MD, PhD
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Thomas W. Flaig, MD
Agensys, Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Aurora Oncology: Equity Interest/Stock Options; Intellectual Property Rights
Bristol Myers Squibb: Grant/Research Support
Criterium, Inc.: Scientific Advisor; Consulting Fee
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Scientific Advisor; Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support
SeaGen: Grant/Research Support
Janet Kukreja, MD
Intuitive Surgical, Inc.: Consulting Fee
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-24-120-H01-P
Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until November 26, 2025. PAs should only claim credit commensurate with the extent of their participation.
Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 1 CE contact hour. Activity Code: S00061295; Approval #: 240003363
Available Credit
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Price
Required Hardware/software
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing